Publications

5434 Results

Effectiveness of adjuvant pembrolizumab improves quality-of-life outcomes compared to high dose interferon or ipilimumab in patients with resected melanoma; SWOG S1404, A Randomized Clinical Trial

Authors
J Unger;A Darke;M Othus;A Tarhini;J Kirkwood;E Sharon;V Sondak;S Guild;T Truong;Z Eroglu;K Kendra;K Lewis;B Faller;P Funchain;E Buchbinder;K Grossmann;A Ribas;S Patel
Journal / Conference
JAMA Oncology Feb 1;9(2):251-260
Year
2023
Research Committee(s)
Melanoma
PMID
PMID36416836
PMC
PMC9685550
Study Number(s)
S1404

Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy from Adjuvant Therapy in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Authors
S Lee;C Ma;Q Shi;P Kumar;F Coutoure;JP Kuebler;S Krishnamurthi;D Lewis;B Tan;R Goldberg;A Venook;CD Blanke;E O'Reilly;A Shields;J Meyerhardt
Journal / Conference
Journal of Clinical Oncology Feb 10;41(5):1079-1091
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID36367997
PMC
PMC9928634
Study Number(s)
CTSU/C80702

Early Mortality Risk with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1,336 Patients from MRC/NCRI and SWOG

Authors
M Othus;I Thomas;X Wang;C Ariti;P Mehta;M Sydenham;R Hills;A Burnett;S Nand;S Assouline;L Michaelis;H Erba;N Russell;K Kerr;R Walter;M Dennis
Journal / Conference
Leukemia and Lymphoma Jan;64(1):250-252
Year
2023
Research Committee(s)
Leukemia and Symptom Control and Quality of Life
PMID
PMID36226777
Study Number(s)
S0432, S0702, S1612

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Authors
J Brown;C Ma;Q Shi;C Fuchs;J Meyer;D Niedzwiecki;T Zemla;F Couture;P Kuebler;P Kumar;D Lewis;B Tan;E O'Reilly;AF Shields;J Meyerhardt
Journal / Conference
Journal of Clinical Oncology Jan 10;41(2):243-254
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID35944235
PMC
PMC9839249
Study Number(s)
CTSU/C80702

Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)

Authors
E Van Blarigan;C Ma;F-S Ou;T Bainter;A Venook;K Ng;D Niedzwiecki;E Giovannucci;H-J Lenz;J Shaw;B Polite;H Hochster;R Goldberg;R Mayer;CD Blanke;E O'Reilly;J Meyerhardt
Journal / Conference
International Journal of Cancer Jan 15;152(2):123-136
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID35904874
PMC
PMC9691576
Study Number(s)
CTSU/C80405

Adjuvant Chemoradiation in Patients with Lymph Node Positive Biliary Tract Cancers: A Secondary Analysis of SWOG S0809 Trial

Authors
S Gholami;S Colby;D Horowitz;K Guthrie;E Ben-Josef;A El-Khoueiry;CD Blanke;P Philip;L Kachnic;S Ahmad;F Rocha
Journal / Conference
Annals of Surgical Oncology Mar;30(3):1354-1363
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID36622529
PMC
PMC10695673
Study Number(s)
S0809

A Randomized Phase II/III Study Of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Age 60 or Older: A Report of the Comparison of Azacitidine and Nivolumab to Azacitidine: SWOG S1612

Authors
S Assouline;L Michaelis;M Othus;A Hay;R Walter;M Jacoby;M Schroeder;G Uy;L Law;F Cheema;K Sweet;A Asch;J Liu;A Moseley;T Maher;L Kingsbury;M Fang;J Radich;R Little;H Erba
Journal / Conference
Leukemia and Lymphoma Feb;64(2):473-477
Year
2023
Research Committee(s)
Leukemia
PMID
PMID36517990
Study Number(s)
S1612

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Authors
E Rodler;Sharma;W Barlow;J Gralow;S Puhalla;C Anders;L Goldstein;D Tripathy;U Brown-Glaberman;T Huynh;C Szyarto;A Godwin;H Pathak;E Swisher;M Radke;K Timms;D Lew;J Miao;L Pusztai;D Hayes;G Hortobagyi
Journal / Conference
Lancet Oncology Feb;24(2):162-174
Year
2023
Research Committee(s)
Breast
PMID
PMID36623515
PMC
PMC9924094
Study Number(s)
S1416

Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in the SWOG S8814 trial

Authors
C Speers;WF Symmans;W Barlow;A Trevarton;S The;L Du;J Rae;S Shak;R Baehner;P Sharma;L Pusztai;G Hortobagyi;D Hayes;K Albain;A Godwin;A Thompson
Journal / Conference
Journal of Clinical Oncology Apr 1;41(10):1841-1848
Year
2023
Research Committee(s)
Breast
PMID
PMID36649570
PMC
PMC10082279
Study Number(s)
SWOG-8814

Quality-of-life outcomes and risk-prediction for advanced lung cancer treated with Nivolumab/Ipilimumab vs Nivolumab

Authors
J Unger;L Qian;M Redman;S Tavernier;L Minasian;E Sigal;V Papadimitrakopoulou;M LeBlanc;C Cleeland;S Dzingle;T Summers;H Chao;S Madhusudhana;L Villaruz;J Crawford;JE Gray;KL Kelly;DR Gandara;L Bazhenova;RS Herbst;S Gettinger;C Moinpour
Journal / Conference
Journal of the National Cancer Institute Jan 10;djad003. doi: 10.1093/jnci/djad003. Online ahead of print
Year
2023
Research Committee(s)
Lung
PMID
PMID36625510
PMC
PMC10086628
Study Number(s)
S1400I